Dr. Saba is a Professor in the Department of Hematology and Medical Oncology and is an adjunct Professor of Otolaryngology. He serves as　the Director of the Head and Neck Cancer Oncology Program at the Winship Cancer Institute. His research is focused on basic, clinical and translational research in head and neck malignancies and has focused on advancing the field in these diseases and improving patient outcome through the identification and clinical development of novel therapeutic approaches and correlative biomarkers. Dr Saba is a well-recognized international leader in the field of head and neck cancer clinical research especially in the area of EGFR targeting and immunotherapeutic applications. He has served as the principal investigator of more than 50 interventional and translational clinical trials and is currently serving as PI on two investigator initiated multi-institutional trials in head and neck cancer; Dr Saba is currently the chair of two cooperative group clinical trials in the field of head and neck oncology under the ECOG-ACRIN group; EA3163 is focusing on intensification of therapy for organ preservation in Sino nasal cancers; and EA3161 is investigating a maintenance anti-PD-1 strategy for the intermediate risk oropharyngeal squamous cell carcinomas. He has also received competitive NIH funding through an R21 grant investigating novel genomic approaches in HPV related and unrelated OPCA; Dr Saba is also the recipient of intramural funding and has been the co-Leader of project 4 of the previously funded Emory HNCA SPORE program; He has also received prior funds through the DOD mechanism; As a result of his recognized leadership role in HNCA research Dr Saba has been named the chair of the recurrent metastatic as well as rare tumor Task Forces of the Head and Neck Cancer NCI steering committee; Dr Saba also has more than 150 peer reviewed manuscripts and textbook chapter publications, and is the editor of a textbook updating the management of esophageal cancer;